PAPILLON Study - Amivantamab + Chemo vs. Chemo as 1L Treatment in EGFR Exon 20 Insertion-Mutated Advanced NSCLC

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

PAPILLON Study - Amivantamab + Chemo vs. Chemo as 1L Treatment in EGFR Exon 20 Insertion-Mutated Advanced NSCLC

By Insights from 2023 ESMO Annual Meeting FEATURING Nicolas Girard

0 views

November 17, 2023

Disclaimer: On March 1, 2024, The FDA has approved amivantamab-vmjw (RYBREVANT®) plus carboplatin and pemetrexed for the frontline treatment of patients with locally advanced or mNSCLC harboring EGFR exon 20 insertion mutations, as detected by an FDA-approved test.

Login

Login

Join VuMedi

PAPILLON Study - Amivantamab + Chemo vs. Chemo as 1L Treatment in EGFR Exon 20 Insertion-Mutated Advanced NSCLC

Recommended